探析中國在應(yīng)對trips-plus條款擴(kuò)張的策略-資料下載頁
2025-06-17 15:26本頁面
【正文】 [M]. Federico Ortino, Oxford University Press,20XX:215237. WTO Panel Report. Canada—Pharmaceutical Patents[R]. WT/DS114/R, 7 April 20XX. C. Fink and P. Reichenmiller. Tightening TRIPS: The Intellectual Property Provisions of Recent US Free Trade Agreements (20XX)[G]s:// The World Bank Group Trade Note, 20XX. JeanFr233。d233。ric Morin. Tripping up TRIPS Debates IP and Health in Bilateral Agreements[J]. Int. J. Intellectual Property Management, Vol. 1, Nos. 1/2, 20XX:37. Malpani, Rohit. All Costs, No Benefits: How the USJordan Free Trade Agreement Affects Access to Medicines[J]. Journal of Generic Medicines, Volume 6,Number 3, 20XX:206217 IMS Health[Z]. 20XX. General Authority for Investment and Free Zones[Z]. GAFI Major Pharmaceutical Markets in the Middle East[M]. Urch Publishing, 20XX. B Lokuge, TA Faunce, R Denniss. A Back Door to Higher Medicine Prices?[G]s:// Intellectual Property and the AustraliaUS Free Trade Agreement,20XX. Dalton A. Australia’s Pharmaceutical Benefits System: Flawed but Improving, and Better Than Anywhere Else[J]. Austral Health Rev., 20XX, 24(2):7–14. [11] Thomas Alured Faunce, Jimmy Bai, Duy Nguyen. Impact of the AustraliaUS Free Trade Agreement on the Australian Medicines Regulation and Prices[J]. Journal of Generic Medicines, Vol. 7, No. 1, 20XX:1829. [12] Mecurio B. The Impact of the Australia United States Free Trade Agreement on the Provision of Health Services in Australia[J]. Whittier Law Rev., 20XX(26): 1051. [13] , Alexander HenryAustralian Pharmaceutical Policy: Price Control, Equity, and Drug Innovation in Australia[J]. Journal of Public Health Policy, Vol. 29, No. 1,20XX [14] Faunce, T. and Lexchin, J. Linkage Evergreening in Canada and Australia,Australian and New Zealand Health Policy[EB/OL][20XX0825].:s:// /content/4/1/8. [15] Zoellick, R. USTR (20XX) Letter to Vaile M, Australian Minister for Trade, [EB/OL].[20XX1005]:s:///trade/negotiations/us_fta/ Expansion of TRIPSplus Provisions and China’s Countermeasures: From the Perspective of Patent Protection for MedicineWU Xueyan (Law School of Chongqing University, Chongqing 400044) Abstract: In recent years, developed countries like the USA and the EU, taking advantage of elastic provisions of the TRIPS, insert lots of TRIPSplus provisions into the FTAs while signing Free Trade Agreements with developing countries with market access and FDI as a lure. The added provisions raise the level of protection of intellectual property through the expansion of TRIPS and creation of higher standards. It is proved that in practice the TRIPSplus provisions have considerably adverse effects on developing countries’ access to essential medicines. As a developing country largely depending on generic drugs, China should be cautious about TRIPSplus provisions while making laws or negotiating free trade treaties with other countries. Key Words: TRIPS。 TRIPSplus。 patent protection。 access to medicine論文在線 :s://
電大資料相關(guān)推薦
鄂ICP備17016276號-1